業績紹介

2015年 論文

  • Continuous use of enzalutamide in a patient who developed enzalutamide-induced thrombocytopenia.
    Sato A, Kosaka T, Oya M.
    BMJ Case Rep. 2015 Nov 25;2015. pii: bcr2015212567. doi: 10.1136/bcr-2015-212567.
  • Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.
    Kumabe A, Fukuhara N, Utsunomiya T, Kawase T, Iwata K, Okada Y, Sutani S, Ohashi T, Oya M, Shigematsu N.
    Radiat Oncol. 2015 Oct 12;10:208. doi: 10.1186/s13014-015-0515-4.
  • CLINICAL BACKGROUND ANALYSIS ABOUT TRANSURETHRAL ELECTROCOAGULATION. Katsui M, Kikuchi E, Yazawa S, Hagiwara M, Morita S, Shinoda K, Kosaka T, Mizuno R, Shinojima T, Asanuma H, Miyajima A, Oya M.
    Nihon Hinyokika Gakkai Zasshi. 2015 Oct;106(4):255-63.
  • Clinical Background of Patients with Sperm in Their Urinary Sediment.
    Tomita M, Kikuchi E, Maeda T, Kabeya Y, Katsuki T, Oikawa Y, Kato K, Ohashi M, Nakamura S, Oya M, Shimada A.
    PLoS One. 2015 Sep 11;10(9):e0136844. doi: 10.1371/journal.pone.0136844. eCollection 2015.
  • Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
    Sutani S, Ohashi T, Sakayori M, Kaneda T, Yamashita S, Momma T, Hanada T, Shiraishi Y, Fukada J, Oya M, Shigematsu N.
    Radiother Oncol. 2015 Nov;117(2):270-6.
  • Coincident detection of lung metastasis of prostate cancer and primary lung cancer: A case report.
    Muro Y, Kosaka T, Hato T, Mikami S, Oya M.
    Can Urol Assoc J. 2015 Jul-Aug;9(7-8):E524-6. doi: 10.5489/cuaj.2376.
  • Comparison of continence outcomes of early catheter removal on postoperative day 2 and 4 after laparoscopic radical prostatectomy: a randomized controlled trial.
    Matsushima M, Miyajima A, Hattori S, Takeda T, Mizuno R, Kikuchi E, Oya M.
    BMC Urol. 2015 Jul 31;15:77. doi: 10.1186/s12894-015-0065-y.
  • Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.
    Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M. Eur Urol Focus. 2015 Aug;1(1):54-63.
  • A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
    Akaza H, Oya M, Iijima M, Hyodo I, Gemma A, Itoh H, Adachi M, Okayama Y, Sunaya T, Inuyama L.
    Jpn J Clin Oncol. 2015 Oct;45(10):953-62. doi: 10.1093/jjco/hyv099. Epub 2015 Jul 22.
  • Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer.
    Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Tanaka N, Kosaka T, Miyajima A, Oya M.
    Mol Cancer Ther. 2015 Sep;14(9):2112-20. doi: 10.1158/1535-7163.MCT-15-0140. Epub 2015 Jul 16.
  • Visceral to total obesity ratio and severe hydronephrosis are independently associated with prolonged pneumoperitoneum operative time in patients undergoing laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma.
    Shigeta K, Kikuchi E, Hagiwara M, Hattori S, Kaneko G, Hasegawa M, Takeda T, Jinzaki M, Akita H, Miyajima A, Nakagawa K, Oya M.
    Springerplus. 2015 Jun 24;4:290. doi: 10.1186/s40064-015-1077-5. eCollection 2015.
  • Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB.
    Muro Y, Kosaka T, Mizuno R, Ohashi T, Shigematsu N, Oya M.
    Am J Clin Exp Urol. 2015 Apr 25;3(1):48-50. eCollection 2015.
  • Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist.
    Ezaki T, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Miyajima A, Oya M.
    Cancer Chemother Pharmacol. 2015 Aug;76(2):301-6. doi: 10.1007/s00280-015-2798-4. Epub 2015 Jun 9.
  • Renin-angiotensin system blockade: Its contribution and controversy.
    Miyajima A, Kosaka T, Kikuchi E, Oya M.
    Int J Urol. 2015 Aug;22(8):721-30. doi: 10.1111/iju.12827. Epub 2015 May 29. Review.
  • Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M, Kikuchi E, Matsumoto K, Hattori S, Takeda T, Kosaka T, Miyajima A, Oya M.
    Int J Oncol. 2015 Jul;47(1):377-83.
  • Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.
    Tamura K, Kikuchi E, Konno T, Ishihara K, Matsumoto K, Miyajima A, Oya M.
    BMC Cancer. 2015 Apr 26;15:317.
  • Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
    Ito Y, Kikuchi E, Tanaka N, Kosaka T, Suzuki E, Mizuno R, Shinojima T, Miyajima A, Umezawa K, Oya M.
    BMC Cancer. 2015 Apr 29;15:324.
  • Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
    Maeda T, Kikuchi E, Hasegawa M, Ishioka K, Hagiwara M, Miyazaki Y, Shinojima T, Miyajima A, Oya M.
    Urology. 2015 May;85(5):1151-5.
  • Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery.
    Miyajima A, Yazawa S, Kosaka T, Tanaka N, Shirotake S, Mizuno R, Kikuchi E, Oya M.
    Ann Surg Oncol. 2015 Oct;22(11):3751-9. doi: 10.1245/s10434-015-4436-0. Epub 2015 Feb 18.
  • How does visceral obesity affect surgical performance in laparoscopic radical nephrectomy?
    Yuge K, Miyajima A, Jinzaki M, Kaneko G, Hagiwara M, Hasegawa M, Takeda T, Kikuchi E, Nakagawa K, Oya M.
    Jpn J Clin Oncol. 2015 Apr;45(4):373-7.
  • Bladder metastasis from renal cell carcinoma: retrospective analysis of 65 reported cases.
    Matsumoto K, Hayakawa N, Nakamura S, Oya M.
    Clin Exp Metastasis. 2015 Feb;32(2):135-41.
  • Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke.
    Ishida M, Mikami S, Shinojima T, Kosaka T, Mizuno R, Kikuchi E, Miyajima A, Okada Y, Oya M.
    Int J Cancer. 2015 Jul 15;137(2):299-310.
  • Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
    Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. J Urol. 2015 Apr;193(4):1122-8.
  • Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y.
    Int J Cancer. 2015 Apr 1;136(7):1504-14.
  • Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary--Japanese Urological Association, 2014 edition).
    Oya M, Kikuchi E; Committee for Establishment of Clinical Practice Guideline for Management of Upper Tract Urothelial Carcinoma; Japanese Urological Association.
    Int J Urol. 2015 Jan;22(1):3-13.
  • Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
    Kondo T, Nakazawa H, Oya M, Kimura G, Fujii Y, Hatano T, Kawata N, Kume H, Morita M, Nakajima K, Ohno Y, Okegawa T, Takahashi S, Wakumoto Y, Horie S, Yamaguchi R, Saito K, Murakami M.
    Jpn J Clin Oncol. 2015 Mar;45(3):274-80.
  • Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer.
    Shigeta K, Kosaka T, Yazawa S, Yasumizu Y, Mizuno R, Nagata H, Shinoda K, Morita S, Miyajima A, Kikuchi E, Nakagawa K, Hasegawa S, Oya M.
    Int J Clin Oncol. 2015 Jun;20(3):605-12.
  • Visceral obesity is associated with better recurrence-free survival after curative surgery for Japanese patients with localized clear cell renal cell carcinoma.
    Kaneko G, Miyajima A, Yuge K, Yazawa S, Mizuno R, Kikuchi E, Jinzaki M, Oya M.
    Jpn J Clin Oncol. 2015 Feb;45(2):210-6.
業績紹介